Clinical trials: Tenofovir
HIV Infections
Kaletra and Viread in Antiretroviral Naïve Patients
Once daily antiretroviral therapy with Viread (tenofovir DF, 300mg) plus Kaletra (LPV/r, 800mg/200mg) will be effective in suppressing and maintaining suppression of HIV RNA to <50 copies/ml in antiretroviral naïve patients…
- Trial name
- NCT00679926
- Testing
- Once daily
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Oklahoma State University Center for Health Sciences
HIV-1 Infection
Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults
The primary objective of this study is to assess glomerular function before and during administration of stribild (STB; elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF)) or a regimen containing TDF…
- Trial name
- NCT02246998
- Testing
- STB, TVD, ATR
- Where
- 20 sites in Belgium, France and 3 more
- Volunteers
- 72 people
- Sponsor
- Gilead Sciences
HIV Infections
Pharmacokinetic and Safety Study of a 90 Day Intravaginal Ring Containing Tenofovir
The purpose of this study is to evaluate the pharmacokinetics (PK) and safety of a 90-day intravaginal ring (IVR) containing tenofovir (TFV).
- Trial name
- NCT03670355
- Testing
- Tenofovir (TFV) IVR
- Where
- 3 sites in United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV/AIDS, HIV Prevention
Tenofovir Rectal Douche to Prevent HIV Transmission Among Adolescents (ATN DREAM)
ATN DREAM is an early phase-1, open label study to examine the safety, pharmacokinetics (PK), pharmacodynamics (PD), and acceptability of a one-dose tenofovir (TFV) medicated douche.
- Trial name
- NCT04686279
- Testing
- Tenofovir Douche
- Where
- 3 sites in United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
HIV Infections
Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men
This study will evaluate the safety and efficacy of the injectable drug cabotegravir (CAB LA), for pre-exposure prophylaxis (PrEP) in HIV-uninfected cisgender men and transgender women who have sex with men (MSM and TGW).
- Trial name
- NCT02720094
- Testing
- Cabotegravir Oral Tablet, TDF/FTC tablets, CAB LA
- Where
- 43 sites in United States, Argentina and 5 more
- Volunteers
- 4,570 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis B, Chronic
Phase 3 Study of GSK548470 in Patients With Compensated Chronic Hepatitis B With Poor Response to Other Drugs
The purpose of this study is to evaluate the efficacy and safety of once-daily treatment with GSK548470 300 mg in Japanese patients with compensated chronic hepatitis B with poor response to other drugs.
- Trial name
- NCT01475851
- Testing
- GSK548470 300 mg tablet
- Where
- 11 sites in Japan
- Volunteers
- 34 people
- Sponsor
- GlaxoSmithKline
Chronic Hepatitis D Infection With Hepatitis B
A Multicenter, Open-label, Randomized Clinical Study to Assess Efficacy and Safety of 3 Doses of Myrcludex B for 24 Weeks in Combination With Tenofovir Compared to Tenofovir Alone to Suppress HBV Replication in Patients With Chronic Hepatitis D
This is a multicenter, open-label, randomized clinical trial to Assess Efficacy and Safety of 3 Doses of Myrcludex B for 24 Weeks in Combination with Tenofovir Compared to Tenofovir Alone to Suppress HBV Replication in Patients…
- Trial name
- NCT03546621
- Testing
- Myrcludex B, Myrcludex-B, Tenofovir
- Where
- 15 sites in Germany, Russia
- Volunteers
- 120 people
- Sponsor
- Hepatera Ltd.
HIV-1 Infection
A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)
The primary objectives of this study are to evaluate the antiretroviral activity of a switch to Doravirine/Islatravir (DOR/ISL) compared with continued Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) at Week 48; and…
- Trial name
- NCT05630755
- Testing
- DOR/ISL, BIC/FTC/TAF
- Where
- 49 sites in United States, Australia and 4 more
- Volunteers
- 514 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
The ADAPT Study: Use of Emtricitabine and Tenofovir Disoproxil Fumarate for Pre-Exposure Prophylaxis (PrEP)
Pre-exposure prophylaxis (PrEP) is a method of preventing HIV infection through the use of antiretroviral (ARV) medications before exposure to HIV.
- Trial name
- ADAPT (NCT01327651)
- Testing
- Daily dosing, Time-driven dosing, Event-driven dosing
- Where
- 3 sites in United States, South Africa and 1 more
- Volunteers
- 622 people, healthy volunteers welcome
- Sponsor
- HIV Prevention Trials Network
HIV-1-infection, Hepatitis B
B/F/TAF Switch Study for HIV-HBV Coinfection
The primary objective of this study is to evaluate the efficacy and safety of fixed dose combination (FDC) bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in adults coinfected with both HIV-1 and hepatitis B.
- Trial name
- BEST-HBV (NCT03797014)
- Testing
- B/F/TAF
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- University of Maryland, Baltimore
HIV
Effects of Biktarvy on CFR in Stable HIV Patients
Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is a single pill regimen that was approved by the FDA in February 2018 for treatment of HIV. The marketed name of the drug is Biktarvy.
- Trial name
- BETTER (NCT03656783)
- Testing
- Biktarvy
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- Brigham and Women's Hospital
HIV Infection
Switch to Unboosted Atazanavir With Tenofovir Study
A drug-drug interaction between the anti-HIV drugs tenofovir DF (TDF) and atazanavir (ATZ) results in lower ATZ plasma levels when the drugs are given together, particularly in patients not taking ritonavir to boost ATZ levels.
- Trial name
- SUAT (NCT01351740)
- Testing
- atazanavir, atazanavir/ritonavir
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- University of British Columbia
HIV Infections
Safety and Pharmacokinetic Study of Tenofovir Alafenamide (TAF)/Elvitegravir (EVG) Administered Rectally
The purpose of this study is to evaluate the safety and pharmacokinetics of rectal administration of a tenofovir alafenamide (TAF)/elvitegravir (EVG) insert at two dose levels in HIV-uninfected individuals.
- Trial name
- NCT04047420
- Testing
- TAF/EVG Insert
- Where
- 2 sites in United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis B, Chronic
A Study of Switching From Entecavir to Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B
Tenofovir Disoproxil Fumarate is a nucleos(t)ide analogue that inhibits Hepatitis B Virus (HBV) growth, and is marketed in Japan with an indication for inhibition of HBV growth in subjects with chronic hepatitis B associated with…
- Trial name
- NCT03258710
- Testing
- Tenofovir Disoproxil Fumarate
- Where
- 18 sites in Japan
- Volunteers
- 75 people
- Sponsor
- GlaxoSmithKline
Chronic Hepatitis B
A Study to Evaluate Tenofovir Disoproxil Fumarate (DF) in Asian-American Adults With Chronic Hepatitis B Infection
The purpose of this study is to evaluate the antiviral activity and safety of tenofovir disoproxil fumarate (TDF) in Asian-American adults (self-reported Asian descent, living in the United States) with chronic hepatitis B…
- Trial name
- NCT00736190
- Testing
- Tenofovir disoproxil fumarate
- Where
- 21 sites in United States
- Volunteers
- 90 people
- Sponsor
- Gilead Sciences
HIV Infections, Lipodystrophy
Effectiveness of Nucleoside Supplementation or Switch to Tenofovir in Reversing Fat Loss in HIV Infected Adults
HIV lipoatrophy is a condition marked by fat loss; it occurs in many patients taking antiretroviral (ARV) therapy that includes nucleoside reverse transcriptase inhibitors (NRTIs).
- Conditions
- HIV Infections, Lipodystrophy, Metabolic Diseases, Nutrition Disorders
- Trial name
- NCT00119379
- Testing
- NucleomaxX, Tenofovir Disoproxil Fumarate
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infection
Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)
This study will evaluate the safety and efficacy of a switch to Doravirine/Islatravir (DOR/ISL) (MK-8591A) (a fixed dose combination of doravirine 100 mg and islatravir 0.75 mg) in participants living with human immunodeficiency…
- Trial name
- NCT04223791
- Testing
- DOR/ISL, BIC/FTC/TAF
- Where
- 89 sites in United States, Australia and 9 more
- Volunteers
- 643 people
- Sponsor
- Merck Sharp & Dohme LLC
Risk Reduction
Urine Tenofovir Point-of-care Test to Identify Patients in Need of ART Adherence Support (UTRA Study)
ART is given to people living with HIV in order to suppress the virus, resulting in improved health for the individual and decreased transmission of the virus to others. Success of ART is dependent on adherence.
- Trial name
- NCT05333679
- Testing
- UTRA, UTRA feedback
- Where
- South Africa
- Volunteers
- 200 people
- Sponsor
- University of California, San Francisco
HIV Infections
Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects
The purpose of Study GS-01-934 was to assess the efficacy and safety of two simplified antiretroviral treatment (ART) regimens in ART-naive, human immunodeficiency virus, type 1 (HIV-1) infected participants.
- Trial name
- NCT00112047
- Testing
- Emtricitabine (FTC), Tenofovir Disoproxil Fumarate (TDF), Efavirenz (EFV)
- Where
- 5 sites in United States
- Volunteers
- 517 people
- Sponsor
- Gilead Sciences
Acute HIV Infection, HIV Infections
Treatment of Acute HIV With Emtricitabine, Tenofovir and Efavirenz (CID 0805)
This is a pilot study of treatment of acute HIV infection with a once daily regimen of Emtricitabine, Tenofovir and Efavirenz. The primary objectives of this study are: 1.
- Trial name
- NCT00924898
- Testing
- efavirenz, emtricitabine, and tenofovir
- Where
- 2 sites in United States
- Volunteers
- 92 people
- Sponsor
- University of North Carolina, Chapel Hill